KOR  ENG

앱클론 로고

Contact

AM109

am109

Immene cell engaging bispecific antibody for
mCRPC (Metastatic Castration-Resistant Prostate Cancer)

AM109 is an AffiMab-based bispecific antibody that kills tumor cells by binding to both T cells and tumor cells.

  • AM109
  • AM109 has tumor cell specific immune cell activation mechanism by targeting to both
    CD137 (4-1BB) on immune cells and PSMA on mCRPC. Using AffiMab format designed to
    exert optimal activation of immune cells, it is expected to have efficient tumor cell killing
    with low toxicity and long-lasting efficacy.
Designed by CHAIRONE
  • 앱클론 로고
  • AbClon Inc. #1401 285, Digital-ro, Guro-gu, Seoul, Republic of Korea
    T. +82-2109-1294
    F. +82-2109-1296
    E. abclon@abclon.com
About us
Overview CAR-T GMP History Collaboration Contact Us
Technology
CAR-T platform NEST platform AffiMab platform
Pipeline
AT101 AT501 AC101 AM201 AM105 AM109
Antibody Service
Antibody Service
IR/PR
News Stock IR Information
© AbClon. All rights reserved.